Immunotherapy

International clinical trial exploring treatment combinations for rare and aggressive cancers in women launched in Australia

Translational findings and higher major pathological response support combinations over monotherapy before surgery

Tedopi® safely improved overall survival and quality of life in patients with hard-to-treat non-small cell lung cancer

The safety profile of cabozantinib observed in the trial was consistent with its known safety profile

Dinutuximab beta therapy augments stem cell transplantation in patients with neuroblastoma

Combination therapy improved median disease-free and overall survival in pancreatic ductal adenocarcinoma cases

Patients with high TMC may generate more proinflammatory immune cells, and therefore, respond better to immunotherapy 

Phase 3 trial establishes safety and overall survival rate of treatment with atezolizumab for non-small cell lung cancer

Trial showed that mRNA-led CAR-T therapy may be a safe and durable treatment option for this rare disease